Construction and immune effect of Haemophilus parasuis DNA vaccine encoding glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in mice
Construction and immune effect of Haemophilus parasuis DNA vaccine encoding glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in mice
复制标题
3-磷酸甘油醛脱氢酶（GAPDH）副猪嗜血杆菌DNA疫苗的构建及小鼠免疫效果
DOI：
10.1016/j.vaccine.2012.09.014
复制
发表时间：
2012-11-06
期刊：
影响因子：
5.5
通讯作者：
Bei, Weicheng
中科院分区：
文献类型：
--
作者：
Fu, Shulin;Zhang, Minmin;Bei, Weicheng
副猪嗜血杆菌是猪多浆液炎、多关节炎和脑膜炎的病原体，是世界上最重要的猪细菌性疾病之一。由于缺乏诱导可靠的跨血清型保护，副猪嗜血杆菌疫苗的开发受到阻碍。本研究发现编码甘油醛-3-磷酸脱氢酶（GAPDH）的gapA基因在副猪嗜血杆菌的多种血清型中均存在并高度保守，并构建了一种编码GAPDH的新型DNA疫苗（pCgap），以评价其对副猪嗜血杆菌MD0322血清型4或SH0165血清型5感染的免疫应答和保护效果。肌肉注射pCgap后，产生了针对GAPDH的显著抗体应答；此外，pCgap DNA疫苗的抗体具有杀菌作用，表明它在体内表达。接种7天后，在小鼠的肌肉、肝脏、脾脏和肾脏中检测到gapA转录本。IgG亚类（IgG1和IgG2a）分析表明，DNA疫苗诱导Th1和Th2免疫应答，但IgG1应答大于IgG2a应答。此外，pCgap疫苗接种组对副猪嗜血杆菌MD0322血清型4和SH0165血清型5攻击的保护效果分别为83.3%和50%。与阴性对照组和空白对照组相比，pCgap DNA疫苗的保护效果显著提高(P
Haemophilus parasuis, the causative agent of swine polyserositis, polyarthritis, and meningitis, is one of the most important bacterial diseases of pigs worldwide. The development of a vaccine against H. parasuis has been impeded due to the lack of induction of reliable cross-serotype protection. In this study the gapA gene that encodes glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was shown to be present and highly conserved in various serotypes of H. parasuis and we constructed a novel DNA vaccine encoding GAPDH (pCgap) to evaluate the immune response and protective efficacy against infection with H. parasuis MD0322 serovar 4 or SH0165 serovar 5 in mice. A significant antibody response against GAPDH was generated following pCgap intramuscular immunization; moreover, antibodies to the pCgap DNA vaccine were bactericidal, suggesting that it was expressed in vivo. The gapA transcript was detected in muscle, liver, spleen, and kidney of the mice seven days post-vaccination. The IgG subclass (IgG1 and IgG2a) analysis indicated that the DNA vaccine induced both Th1 and Th2 immune responses, but the IgG1 response was greater than the IgG2a response. Moreover, the groups vaccinated with the pCgap vaccine exhibited 83.3% and 50% protective efficacy against the H. parasuis MD0322 serovar 4 or SH0165 serovar 5 challenges, respectively. The pCgap DNA vaccine provided significantly greater protective efficacy compared to the negative control groups or blank control groups (P